Article
Medicine, Research & Experimental
Yasuyuki Tamai, Zhen Chen, Yue Wu, Jun Okabe, Yoshinao Kobayashi, Hitoshi Chiba, Shu-Ping Hui, Akiko Eguchi, Motoh Iwasa, Masaaki Ito, Yoshiyuki Takei
Summary: The combined treatment of BCAA and L-carnitine significantly improved hepatocellular function, reduced lipid deposition and adipophilin expression, and protected the liver by maintaining mitochondrial integrity in cirrhotic rats, supporting their therapeutic potential in human chronic liver diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Medicine, General & Internal
Anne M. M. van Dijk, Alexandra S. Bruins S. Slot, Piero Portincasa, Sebastiaan N. Siegerink, Najiba Chargi, Carina J. R. Verstraete, Joep de Bruijne, Frank P. P. Vleggaar, Karel J. J. van Erpecum
Summary: Prophylactic supplementation of BCAA appears to be safe and may improve survival in cirrhotic patients.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Biochemistry & Molecular Biology
Emily Kwun Kwan Lo, Felicianna, Jing-Hang Xu, Qiao Zhan, Zheng Zeng, Hani El-Nezami
Summary: Branched-chain amino acids (BCAAs) are related to chronic liver diseases, but BCAA supplementation has positive effects on cirrhosis and hepatocellular carcinoma (HCC) patients. This review aims to clarify the contradictory claims and study the role of BCAAs in liver health.
Article
Fisheries
Yuliang Wei, Zhiyuan Sun, Mei Duan, Qiang Ma, Houguo Xu, Mengqing Liang
Summary: The study found that the growth of tiger puffer was not affected by diets containing 12.6-55.9 g kg(-1) leucine. An excess of dietary leucine, isoleucine, or valine possibly resulted in antagonism between BCAAs, showing that excessive intake of one BCAA may lead to antagonistic effects when the other two BCAAs met the requirements for tiger puffer.
Review
Oncology
Georgios A. Sideris, Savvas Tsaramanidis, Aikaterini T. Vyllioti, Njogu Njuguna
Summary: Numerous studies have investigated the use of branched-chain amino acid (BCAA) supplements in patients with cirrhosis and liver cancer, with reported benefits including improved survival rates and hepatic functional reserve. However, the potential role of BCAA supplementation in conjunction with locoregional therapies for liver cancer remains unclear. A systematic review and meta-analysis of articles investigating BCAA supplementation in patients with hepatocellular carcinoma undergoing interventional radiology procedures revealed significantly higher post-treatment albumin levels, suggesting potential benefits in combination with locoregional treatments. However, current data are insufficient to support additional benefits.
Article
Oncology
Atsushi Hiraoka, Masaya Kato, Kaori Marui, Taisei Murakami, Kei Onishi, Tomoko Adachi, Junko Matsuoka, Hidetaro Ueki, Takeaki Yoshino, Miho Tsuruta, Toshihiko Aibiki, Tomonari Okudaira, Taira Kuroda, Ryuichiro Iwasaki, Yoshifumi Suga, Hideki Miyata, Tomoyuki Ninomiya, Masashi Hirooka, Masanori Abe, Bunzo Matsuura, Kojiro Michitaka, Yoichi Hiasa
Summary: The study revealed that a low branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is closely associated with the prognosis of patients with hepatocellular carcinoma (HCC), and the albumin-bilirubin (ALBI) score can serve as an alternative method to evaluate BTR imbalance.
Article
Nutrition & Dietetics
Arun Singh Tejavath, Amit Mathur, Deepak Nathiya, Pratima Singh, Preeti Raj, Supriya Suman, Payal Ramakant Mundada, Sheikh Atif, Ramesh Roop Rai, Balvir Singh Tomar
Summary: The study demonstrated that long-term BCAAs supplementation improved sarcopenia and prognostic markers in patients with advanced LC, leading to significant improvements in muscle strength, function, and mass, and reducing cirrhotic-related complications and event occurrence rate compared to L-ALB group.
FRONTIERS IN NUTRITION
(2021)
Review
Genetics & Heredity
Can Chen, Hassan Naveed, Keping Chen
Summary: This article introduces the important role of branched-chain amino acid aminotransferases in cellular metabolism, summarizes the related research in animals, plants, microorganisms, and humans, and analyzes the molecular mechanism. It has been found that disorders in branched-chain amino acid metabolism are closely related to various diseases, especially tumor development.
FRONTIERS IN GENETICS
(2023)
Article
Nutrition & Dietetics
Katarzyna Paczkowska, Dominik Rachon, Andrzej Berg, Jacek Rybka, Katarzyna Kapczynska, Marek Bolanowski, Jacek Daroszewski
Summary: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that predisposes women to metabolic disturbances. Recent research suggests that alterations in amino acid profiles may be indicative of metabolic disorders. This study found elevated levels of aromatic amino acids in PCOS women, and significant differences in amino acid concentrations between metabolically healthy and unhealthy obesity subgroups of PCOS women.
Review
Gastroenterology & Hepatology
Giuseppe Marrone, Amato Serra, Luca Miele, Marco Biolato, Antonio Liguori, Antonio Grieco, Antonio Gasbarrini
Summary: Liver cirrhosis is often accompanied by nutritional alterations, affecting about 20% of patients with compensated disease and over 60% of patients with decompensated cirrhosis. Imbalance of amino acids, especially branched-chain amino acids (BCAAs), has been shown to be associated with complications and prognosis in these patients. Various studies have explored the use of BCAAs supplementation as a therapeutic option, but uncertainties persist regarding its real efficacy, optimal administration route, and dosage.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Cell Biology
Michaela E. Trautman, Nicole E. Richardson, Dudley W. Lamming
Summary: The proportion of people suffering from age-related diseases is increasing worldwide. Recent research has shown that low protein diets, particularly those low in branched-chain amino acids (BCAAs), can reduce mortality and promote metabolic health and extended lifespan in both humans and rodents. This article discusses the emerging evidence that BCAAs play a crucial role in healthy metabolism and longevity, and explores the physiological and molecular mechanisms behind the benefits of restricting dietary BCAAs. The findings suggest that the quality of protein, specifically the composition of dietary protein, may be a previously overlooked factor in metabolic dysfunction and reducing dietary BCAAs could be a promising new approach to delaying and preventing age-related diseases.
Article
Pharmacology & Pharmacy
Tiangang Wu, Mengling Wang, Fengling Ning, Shilin Zhou, Xuetao Hu, Hong Xin, Svetlana Reilly, Xuemei Zhang
Summary: Fibrosis, characterized by excessive production of extracellular matrix, is a common pathological feature of organ diseases. Metabolic alterations, especially in the regulation of branched-chain amino acids (BCAAs), have been found to play significant roles in fibrogenesis. Dysregulation of BCAAs metabolism has been implicated in various diseases. This review summarizes the metabolic regulation of fibrosis, changes in BCAAs metabolism associated with fibrosis, and the effects and mechanisms of BCAAs intervention in hepatic, renal, and cardiac fibrosis, with a focus on liver fibrosis and associated hepatocellular carcinoma.
PHARMACOLOGICAL RESEARCH
(2023)
Letter
Genetics & Heredity
Sinziana Stanescu, Amaya Belanger-Quintana, Borja Manuel Fernandez-Felix, Francisco Arrieta, Victor Quintero, Maria Soledad Maldonado, Patricia Alcaide, Mercedes Martinez-Pardo
Summary: The study revealed that in patients with propionic acidemia, dietary habits and branched-chain amino acid balance may be associated with severe anemia.
ORPHANET JOURNAL OF RARE DISEASES
(2021)
Review
Chemistry, Applied
Huijia Lu, Zhen Wang, Bo Cao, Fang Cong, Xingguo Wang, Wei Wei
Summary: This paper provides an overview of the molecular species, biosynthesis, distribution of BCFAs, and discusses their effects on intestinal health, immune regulation, anti-carcinoma, and anti-obesity activities.
Article
Oncology
Michelle Junyi He, Wenjun Pu, Xi Wang, Xiaoni Zhong, Dong Zhao, Zhipeng Zeng, Wanxia Cai, Jiayi Liu, Jianrong Huang, Donge Tang, Yong Dai
Summary: This study utilized mass spectrometry mediated spatial metabolomics technique to investigate the metabolic changes in hepatocellular carcinoma (HCC). The results revealed that amino acid metabolism and glycerophospholipid metabolism exhibited the most significant alterations during HCC progression, and these altered metabolites and pathways were interconnected through the urea cycle.
CANCER CELL INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Akihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, Yasuhito Tanaka, Noboru Shinkai, Chiaki Okuse, Jong-Hon Kang, Takeshi Matsui, Shiho Miyase, Hiroshi Yatsuhashi, Shinya Nagaoka, Tatsuo Kanda, Masaru Enomoto, Ryoko Yamada, Naoki Hiramatsu, Satoru Saito, Koichi Takaguchi, Kiyoaki Ito, Tsutomu Masaki, Daisuke Morihara, Masataka Tsuge, Kazuaki Chayama, Fusao Ikeda, Tatehiro Kagawa, Yasuteru Kondo, Kazumoto Murata, Eiji Tanaka
JOURNAL OF GASTROENTEROLOGY
(2020)
Article
Medicine, General & Internal
Ryo Fukuda, Shunichi Sugawara, Yasuteru Kondo
Article
Gastroenterology & Hepatology
Yasuteru Kondo, Motoh Iwasa, Hideto Kawaratani, Hisamitsu Miyaaki, Tatsunori Hanai, Kazuyoshi Kon, Hirotaka Hirano, Masahito Shimizu, Hitoshi Yoshiji, Kiwamu Okita, Kazuhiko Koike
Summary: This study aimed to establish the cut-off values of the Stroop test for screening covert hepatic encephalopathy, with results showing a significant correlation between the cut-off values of the Stroop test results and age. The Stroop test was confirmed as a simple tool for assessing cognitive alterations.
HEPATOLOGY RESEARCH
(2021)
Article
Medicine, General & Internal
Isao Hidaka, Masaru Enomoto, Syuichi Sato, Atsushi Suetsugu, Tomomitsu Matono, Kiyoaki Ito, Koji Ogawa, Jun Inoue, Mika Horino, Yasuteru Kondo, Isao Sakaida, Masaaki Korenaga
Summary: Healthcare professionals have a high level of awareness about HBV and HCV, but there is still room for improvement in referring patients to hepatologists. More widespread education of healthcare personnel is important to ensure patients receive appropriate treatment.
Article
Gastroenterology & Hepatology
Kazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, Sadatsugu Sakane, Olivier Govaere, Simon Cockell, Daisuke Motooka, Naruyasu Kakita, Yukinori Yamada, Yasuteru Kondo, Yuki Tahata, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Yoshihiro Kamada, Ann K. Daly, Quentin M. Anstee, Tomohide Tatsumi, Eiichi Morii, Tetsuo Takehara
Summary: The study conducted global RNA sequencing of liver tissue from 98 NAFLD patients, identifying THBS2 as a potential biomarker for NASH and advanced fibrosis. Serum TSP-2 levels were independent predictors of NASH and advanced fibrosis, stratifying patients based on the risk of hepatic complications.
Article
Gastroenterology & Hepatology
Takeshi Matsui, Susumu Hamada-Tsutsumi, Yutaka Naito, Masanori Nojima, Etsuko Iio, Akihiro Tamori, Shoji Kubo, Tatsuya Ide, Yasuteru Kondo, Yuichiro Eguchi, Atsumasa Komori, Yuji Morine, Mitsuo Shimada, Tohru Utsunomiya, Ken Shirabe, Koichi Kimura, Yoichi Hiasa, Natthaya Chuaypen, Pisit Tangkijvanich, Aya Naiki-Ito, Satoru Takahashi, Takahiro Ochiya, Yasuhito Tanaka
Summary: The miRNA clusters miR-183/96/182 and miR-217/216a/216b are significantly upregulated in nonviral hepatocellular carcinoma (NBNC-HCC). High levels of miR-182-5p and miR-217-5p, but low levels of miR-96-5p, in tumor tissues are associated with poor recurrence-free survival of NBNC-HCC patients. Further upregulation of miR-96-5p in tumors may have an inhibitory effect on recurrence, suggesting its potential as a tumor suppressor in NBNC-HCC patients at high risk of recurrence. Transfection of miR-96-5p mimic induced apoptosis of HepG2 cells and suppressed proliferation and invasion, indicating its potential antitumor effects.
HEPATOLOGY RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Hiromasa Ohira, Atsushi Takahashi, Mikio Zeniya, Masanori Abe, Teruko Arinaga-Hino, Satoru Joshita, Akinobu Takaki, Nobuhiro Nakamoto, Jong-Hon Kang, Yoshiyuki Suzuki, Tsuyosi Sogo, Ayano Inui, Kazuhiko Koike, Kenichi Harada, Yasunari Nakamoto, Yasuteru Kondo, Takuya Genda, Koichi Tsuneyama, Tsuyoshi Matsui, Atsushi Tanaka
HEPATOLOGY RESEARCH
(2022)
Article
Multidisciplinary Sciences
Yasuteru Kondo, Junichi Akahira, Tatsuki Morosawa, Yukihiro Toi, Akashi Endo, Hiroaki Satio, Mareyuki Endo, Shunichi Sugawara, Yasuhito Tanaka
Summary: Various iCIs have been found to induce immune-related liver damage. In this retrospective study, NSCLC patients treated with PD-1 antibodies were analyzed to identify useful biomarkers for diagnosing iCIs-related hepatitis. The presence of anti-nuclear antibodies and characteristic liver histology were found to be potential biomarkers for iCIs-related hepatitis in NSCLC patients.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kazuo Okumoto, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Yasuhiro Takikawa, Takuji Torimura, Tomokazu Matsuura, Masatoshi Ishigami, Kazuhiko Koike, Hitoshi Yoshiji
Summary: This study found that long-term treatment with rifaximin is effective and safe for patients with hepatic encephalopathy. Ammonia levels significantly improved after 3 months of treatment and remained improved until 12 months. There were no serious adverse events reported, and the incidence of overt hepatic encephalopathy was low.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Yasuteru Kondo, Tatsuki Morosawa, Soichiro Minami, Yasuhito Tanaka
Summary: This study analyzed the efficacy and safety of drug-eluting beads-transcatheter arterial chemoembolization with low-dose FP therapy in difficult-to-treat hepatocellular carcinoma (HCC) patients. The results showed that Ultra-FP therapy had a high objective response rate and overall survival in difficult-to-treat HCC patients.
SCIENTIFIC REPORTS
(2022)
Article
Pharmacology & Pharmacy
Junji Furuse, Namiki Izumi, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, Katsuaki Motoyoshi, Masatoshi Kudo
Summary: This study aimed to evaluate the real-world safety and effectiveness of Lenvatinib for unresectable hepatocellular carcinoma (uHCC) in clinical practice in Japan. Data of 703 uHCC patients were analyzed, and it was found that the treatment response rate and median overall survival of Lenvatinib were similar to or better than the results of the global Phase III REFLECT trial.
DRUGS-REAL WORLD OUTCOMES
(2023)
Article
Oncology
Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, Katsuya Nagaoka, Takehisa Watanabe, Hiroko Setoyama, Kotaro Fukubayashi, Motohiko Tanaka, Yasuhito Tanaka
Summary: This study aimed to evaluate the impact of therapeutic modifications of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (uHCC). Patients with therapeutic modifications other than discontinuation of both drugs had favorable overall survival and time to progression, while those with discontinuation of both drugs had unfavorable outcomes. Modified liver function and immune-related adverse events increased the risk of discontinuation without other therapeutic modifications. Avoiding discontinuation without other therapeutic modifications may be the optimal management for uHCC.
Article
Oncology
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai
Summary: The TACTICS-L trial investigated the efficacy and safety of TACE plus lenvatinib in patients with unresectable intermediate-stage HCC. The results showed that LEN-TACE has significant anti-tumor activity and an acceptable safety profile.
Meeting Abstract
Medicine, Research & Experimental
Jun-Ichi Akahira, Yasuteru Kondo, Mareyuki Endo
LABORATORY INVESTIGATION
(2020)
Meeting Abstract
Pathology
Jun-Ichi Akahira, Yasuteru Kondo, Mareyuki Endo